Faculty & Staff

Nicolas Barthélemy obtained his PhD in analytical chemistry from the University of Strasbourg. He specializes in protein characterization and quantitation by mass spectrometry. He joined the Bateman laboratory as postdoctoral associate in 2015. As research instructor, Barthélemy focuses his research on tau protein phosphorylation in Alzheimer’s disease and tau modifications in other tauopathies. His research led to the discovery of new tau biomarkers for AD, including ptau217 in plasma/spinal fluid, and has provided new understanding on molecular mechanisms involved in tauopathies.

Kanta Horie is an Eisai-sponsored visiting researcher in Department of Neurology at Washington University.  He obtained his PhD in pharmacy from Kyoto University and specializes in proteomics and metabolomics research.  He joined Bateman’s laboratory in 2019.  His current interests center around translational research in neurodegenerative diseases using various analytical techniques e.g., mass spectrometry and the use for biomarker-driven medicine creation.

Justin Melendez received his PhD in genetics and genomics from Washington University in St. Louis where he worked on developing tools for molecular biology and sequencing technologies. His work in the Bateman lab focuses on studying the connection between human aging and neurodegenerative disease, understanding how and why we age and developing therapeutic interventions to extend human life and health span.

Soumya Mukherjee is a research instructor in the Department of Neurology at Washington University in St. Louis. He obtained his PhD in chemistry from the University of Calcutta and specializes in proteomics and mass spectrometry. He joined the Bateman lab in 2022. His current research interests are in understanding the molecular mechanisms in neurodegeneration and the role protein post-translational modifications (PTMs) has to play during disease progression. Specifically he is interested in the 1) cross-talk of PTMs during disease staging, 2) protein aging and 3) altered proteoforms in neurodegenerative diseases. His goals are in translation of these findings using analytical techniques for the development of disease biomarkers.